ReviewApplied microbiology and biotechnology2026
Nanoparticle-based approaches for bacterial detection and therapy.
Review in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Zinc oxide-bacteriophage synergistic combination for dual-mode antibacterial activity against multidrug-resistant Escherichia coli.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Natural Products and Antimicrobial Nanoparticles Against Methicillin-ResistantPharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of nanotechnology has revolutionised approaches to identifying and combating bacterial infections. This review highlights the latest applications of nanoparticles (NPs) for bacterial detection and treatment, with a focus on their translational potential in clinical settings. We discuss advanced nanotechnology-enabled biosensing platforms that offer ultra-sensitive, rapid and precise diagnostics capabilities crucial for addressing antibiotic-resistant pathogens. In addition to detection, various nanoparticles demonstrate multiple antibacterial mechanisms and function as targeted drug-delivery vehicles. The review also examines current clinical trials involving nanoparticle-based therapeutics, underscoring their promise for overcoming antimicrobial resistance. KEY POINTS: • Nanoparticles enable rapid and sensitive detection of bacterial infections. • Multiple antibacterial mechanisms improve efficacy against resistant pathogens. • Translational challenges must be addressed for successful clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.